Regenxbio Inc
NASDAQ:RGNX

  • LAST PRICE
    8.5900
  • TODAY'S CHANGE (%)
    -0.2500 (-2.8281%)
  • Bid / Lots
    8.5500/ 2
  • Ask / Lots
    8.9000/ 7
  • Open / Previous Close
    8.8000 / 8.8400
  • Day Range
    8.5650
    8.9847
  • 52 Week Range
    8.5650
    28.8000
  • Volume
    502,230

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
RGNX
Regenxbio Inc
436.9M
-1.6x
---
GRAL
Grail Inc
422.9M
-0.1x
---
SAGE
SAGE Therapeutics Inc
393.2M
-1.1x
---
ALEC
Alector Inc
496.3M
-2.7x
---
URGN
Urogen Pharma Ltd
548.3M
-3.8x
---
CDXC
Chromadex Corp
271.8M
-193.9x
---
As of 2024-10-31

Company Information

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Contact Information

Headquarters
9804 Medical Center DriveROCKVILLE, MD, United States 20850
Phone
240-552-8181
Fax
302-655-5049

Executives

Chairman of the Board
Kenneth Mills
President, Chief Executive Officer, Director
Curran Simpson
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Mitchell Chan
Executive Vice President, Chief Scientific Officer
Olivier Danos
Executive Vice President, Chief Legal Officer
Patrick Christmas

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$436.9M
Revenue (TTM)
$89.0M
Shares Outstanding
49.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.21
EPS
$-5.27
Book Value
$7.08
P/E Ratio
-1.6x
Price/Sales (TTM)
4.9
Price/Cash Flow (TTM)
---
Operating Margin
-279.37%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.